198 related articles for article (PubMed ID: 17074266)
21. [Characterization of the katG, inhA, ahpC, kasA, and oxyR gene mutations in isoniazid-resistant and susceptible strain of Mycobacterium tuberculosis by automated DNA sequencing].
Chen X; Ma Y; Jin Q; Jiang GL; Li CY; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Apr; 28(4):250-3. PubMed ID: 15854436
[TBL] [Abstract][Full Text] [Related]
22. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
[TBL] [Abstract][Full Text] [Related]
23. Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis.
Campanerut-Sá PA; Ghiraldi-Lopes LD; Meneguello JE; Fiorini A; Evaristo GP; Siqueira VL; Scodro RB; Patussi EV; Donatti L; Souza EM; Cardoso RF
Future Microbiol; 2016 Sep; 11():1123-32. PubMed ID: 27545345
[TBL] [Abstract][Full Text] [Related]
24. Superoxide reactivity of KatG: insights into isoniazid resistance pathways in TB.
Ghiladi RA; Cabelli DE; Ortiz de Montellano PR
J Am Chem Soc; 2004 Apr; 126(15):4772-3. PubMed ID: 15080669
[TBL] [Abstract][Full Text] [Related]
25. Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.
Shenai S; Rodrigues C; Mehta A
Int J Infect Dis; 2009 Jan; 13(1):46-58. PubMed ID: 18565777
[TBL] [Abstract][Full Text] [Related]
26. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
27. [The use of gene chip in detecting Mycobacterium tuberculosis resistant to rifampin and isoniazid].
Cui ZL; Jing FX; Hu ZY; Wu ZR; Zhao JL
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):439-41. PubMed ID: 15312553
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors.
Shingnapurkar D; Dandawate P; Anson CE; Powell AK; Afrasiabi Z; Sinn E; Pandit S; Venkateswara Swamy K; Franzblau S; Padhye S
Bioorg Med Chem Lett; 2012 May; 22(9):3172-6. PubMed ID: 22475559
[TBL] [Abstract][Full Text] [Related]
29. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
30. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Sriram D; Yogeeswari P; Yelamanchili Priya D
Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
[TBL] [Abstract][Full Text] [Related]
31. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
32. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
Schaaf HS; Victor TC; Venter A; Brittle W; Jordaan AM; Hesseling AC; Marais BJ; van Helden PD; Donald PR
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1355-9. PubMed ID: 19861006
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
Hearn MJ; Cynamon MH
J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
[TBL] [Abstract][Full Text] [Related]
34. Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals.
Romero B; Aranaz A; Bezos J; Alvarez J; de Juan L; Tariq Javed M; Mateos A; Gómez-Mampaso E; Domínguez L
Tuberculosis (Edinb); 2007 Nov; 87(6):565-71. PubMed ID: 17900988
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines.
Herrera L; Valverde A; Saiz P; Sáez-Nieto JA; Portero JL; Jiménez MS
Int J Antimicrob Agents; 2004 Jun; 23(6):572-6. PubMed ID: 15194127
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between catalase activity, KatG gene and isoniazid-resistance in M. tuberculosis].
Wang X; Han Q; Liang B
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Mar; 21(3):174-7. PubMed ID: 11263357
[TBL] [Abstract][Full Text] [Related]
37. [Construction and efficacy study of a novel 10-23 deoxyribozyme expression vector].
Li JM; Wan LG; Zhang CC; Wang N; Luo Q
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(38):2708-12. PubMed ID: 20137274
[TBL] [Abstract][Full Text] [Related]
38. [Resistance-conferring mutations of Mycobacterium tuberculosis strains with low level resistance to isoniazid].
Ano H; Matsumoto T; Nagai T; Tamura Y; Yoshida H; Kawahara K; Takamatsu I; Tsuyuguchi I; Takashima T
Kekkaku; 2006 Dec; 81(12):709-13. PubMed ID: 17240915
[TBL] [Abstract][Full Text] [Related]
39. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.
Zhang Y; Heym B; Allen B; Young D; Cole S
Nature; 1992 Aug; 358(6387):591-3. PubMed ID: 1501713
[TBL] [Abstract][Full Text] [Related]
40. Blood agar for susceptibility testing of Mycobacterium tuberculosis against first-line drugs.
Coban AY; Cihan CC; Bilgin K; Uzun M; Akgunes A; Cetinkaya E; Durupinar B
Int J Tuberc Lung Dis; 2006 Apr; 10(4):450-3. PubMed ID: 16602412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
